The Problem

Heart disease remains the leading cause of death worldwide, with an estimated 17.9 million deaths each year.

Our Solutions

Samba Biologics has developed biologic tools and treatments that save tissue after heart attack.

Samba BioLogics, Inc. is a preclinical stage biotechnology company based in Vermont. We produce breakthrough agonist biologics that preserve tissue and improve repair after ischemic injury. Our pipeline includes “Cell-Kro,” a biologic drug that promotes engraftment of transplanted progenitor cells, and “VasaPlex,” a biologic that rescues jeopardized cardiac tissue after myocardial infarction.

Our Mission

To harness scientific discovery to heal the people that matter most to you.

Our Vision

To be the world’s leading provider of groundbreaking solutions in regenerative medicine that improve quality of life.

Recent News

View recent company news and industry insights.

Samba BioLogics Selected for MassBio’s Biotech Accelerator, MassBioDrive in Spring 2023 Cohort of Startups

The latest cohort of MassBioDrive, a key initiative of MassBio’s innovation programming designed to support entrepreneurs and startups, was announced today by MassBio and features…

Samba BioLogics, Inc. Awarded NIH SBIR/STTR Program Grant

VasaPlex-based biologics for treatment of reperfusion injury after myocardial infarction.

Samba BioLogics Selected for NIH-sponsored DRIVEN Program

Samba BioLogics, Inc. was selected for the NIH-sponsored DRIVEN Program to commercialize our biologics + IP (incubator at Celdara Medical, LLC; West Lebanon, New Hampshire).